OrPro Therapeutics, Inc (San Diego, CA)
OrPro Therapeutics, Inc. (San Diego, CA) is a privately-held preclinical-stage company developing a non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus. The company’s core technology was licensed exclusively from National Jewish Health (NJH, Denver, CO), the leading US respiratory hospital, with key patent-protected improvements (the Theradux® platform) developed internally. OrPro is pursuing a platform/product strategy for in-house commercialization with selected out-licensing.
OrPro has assembled a top R&D team of scientists and consultants with expertise and capabilities in protein chemistry, mucosal immunology, biologic drug manufacturing and formulation, aerosol delivery, inhalation toxicology, preclinical and clinical development, project management, and regulatory affairs. In order to advance its lead product ORP-100S for cystic fibrosis (CF) and non-CF bronchiectasis (BE) the company has established collaborations with key opinion-leading academic scientists and pulmonologists from the CF Centers at NJH, the University of North Carolina at Chapel Hill, and the University of Alabama-Birmingham, with research support from the Cystic Fibrosis Foundation and the National Institutes of Health. OrPro’s operations are based at the flagship La Jolla, CA campus of JLABS, the premier biotech incubator located in the heart of the Torrey Pines Mesa. As a JLABS resident company OrPro has cost-effective access to state-of-the-art shared laboratory facilities and a complete suite of fully-maintained analytic equipment in addition to a dedicated OrPro protein chemistry lab. To date OrPro has raised $2.9M in non-dilutive grant funding and $2.3M in equity financing.